Vaccines against respiratory syncytial virus: The time has finally come

Vaccine. 2016 Jun 24;34(30):3535-41. doi: 10.1016/j.vaccine.2016.04.083. Epub 2016 May 13.


Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality.

Keywords: Asthma; Bronchiolitis; Elderly; Eosinophilia; Epitope; Fusion; Immunization; Infants; Neutralization; Pneumonia; Protein conformation; RSV; Structure-based vaccine design; Subunit vaccine; Th2; Vaccination; Vaccine vector; Vaccine-enhanced illness; Wheezing.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Aged
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Child, Preschool
  • Humans
  • Infant
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Virus Vaccines / immunology*
  • Respiratory Syncytial Virus, Human
  • Viral Fusion Proteins / immunology*


  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Respiratory Syncytial Virus Vaccines
  • Viral Fusion Proteins